Article information
Full text is only aviable in PDF
Bibliografía
[1.]
C.G. Whitney, M.M. Farley, J. Hadler, L.H. Harrison, C. Lexau, A. Reingold, et al.
Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States.
N Engl J Med, 343 (2000), pp. 1917-1924
[2.]
S.J. Schrag, B. Beall, S.F. Dowell.
Limiting the spread of resistant pneumococci: biological and epidemiologic evidence for the effectiveness of alternative interventions.
Clin Microbiol Rev, 13 (2000), pp. 588-601
[3.]
J. Oteo, J.I. Alós, J.L. Gómez-Garcés.
Antimicrobial resistance of Streptococcus pneumoniae isolates in 1999 and 2000 in Madrid, Spain: a multicentre surveillance study.
J Antimicrob Chemother, 47 (2001), pp. 215-218
[4.]
L. Aguilar, C. García-Rey, M.J. Jiménez.
Presión antibiótica, desarrollo de resistencias en Streptococcus pneumoniae y fracaso clínico: un círculo no tan vicioso.
Rev Esp Quimioter, 14 (2001), pp. 17-21
[5.]
D.K. Chen, A. McGeer, J.C. de Azavedo, D.E. Low.
for the Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.
N Engl J Med, 341 (1999), pp. 233-239
[6.]
J. Liñares, A.G. de la Campa, R. Pallarés.
Fluoroquinolone resistance in Streptococcus pneumoniae.
N Engl J Med, 341 (1999), pp. 1546-1548
[7.]
R. Davidson, R. Cavalcanti, J.L. Brunton, D.J. Bast, J.C.S. de Azavedo, P. Kisbey, et al.
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
N Engl J Med, 346 (2002), pp. 747-750
[8.]
C. Urban, N. Rahman, X. Zhao, N. Mariano, S. Segal-Maurer, K. Drlica, et al.
Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy.
J Infect Dis, 184 (2001), pp. 794-798
[9.]
P.E. Empey, H.R. Jennings, A.C. Thornton, R.P. Rapp, M.E. Evans.
Levofloxacin failure in a patient with pneumococcal pneumonia.
Ann Pharmacother, 35 (2001), pp. 687-690
[10.]
J.J. Ross.
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
N Engl J Med, 347 (2002), pp. 65-67
[11.]
T.A. Davies, A. Evangelista, S. Pfleger, K. Bush, D.F. Sham, R. Goldschmidt.
Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000.
Antimicrob Agents Chemother, 46 (2002), pp. 119-124
[12.]
G.G. Zhanel, D.J. Hoban, C.K. Chan.
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
N Engl J Med, 347 (2002), pp. 65-67
[13.]
P.L. Ho, W.S. Tse, K.W.T. Tsang, T.K. Kwok, T.K. Ng, Cheng VCC, et al.
Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study.
Clin Infect Dis, 32 (2001), pp. 701-707
[14.]
F.J. Schmitz, J. Verhoef, D. Milatovic, A.C. Fluit.
Treatment options for Streptococcus pneumoniae strains resistant to macrolides, tetracycline, quinolones, or trimethoprim/sulfamethoxazole.
Eur J Microbiol Infect Dis, 20 (2001), pp. 827-829
[15.]
J. Quale, D. Landman, J. Ravishankar, C. Flores, S. Bratu.
Streptococcus pneumoniae, Brooklin, New York: fluoroquinolone resistance at our doorstep, Emerg Infect Dis, 8 (2002), pp. 594-597
[16.]
F.J. Schmitz, A. Fischer, M. Boss, S. Mayer, D. Milatovic, A.C. Fluit.
Quinolone-resistance mechanisms and in vitro susceptibility patterns among European isolates of Streptococcus mitis, Streptococcus sanguis and Streptococcus pneumoniae.
Eur J Clin Microbiol Infect Dis, 20 (2001), pp. 219-222
[17.]
G.S. Tillotson, X. Zhao, K. Drlica.
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
N Engl J Med, 347 (2002), pp. 65-67
[18.]
D.E. Low, J. de Azavedo, D. Bast.
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
N Engl J Med, 347 (2002), pp. 65-67
[19.]
F. Baquero.
Low-level antibacterial resistance: a gateway to clinical resistance.
Drug Resist Updat, 4 (2001), pp. 93-105
[20.]
D.E. Low, J. de Azavedo, K. Weiss, T. Mazzulli, M. Kuhn, D. Church, et al.
Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000.
Antimicrob Agents Chemother, 46 (2002), pp. 1295-1301
[21.]
J.D. Heffelfinger, S.F. Dowell, J.H. Jorgensen, K.P. Klugman, L.R. Mabry, D.M. Musher, et al.
Management of community-acquired pneumonia in the era of pneumococcal resistance.
Arch Intern Med, 160 (2000), pp. 1399-1480
[22.]
S. Cruchaga, J. Oteo, J.A. Sáez, J. Campos, F. Baquero.
Sistema Europeo de vigilancia EARSS: resistencia antibiótica en cepas invasivas de S. pneumoniae (España 2000).
Enferm Infecc Microbiol Clin, 20 (2002), pp. 101
[23.]
P.D. Lister, C.C. Sanders.
Pharmacodinamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae.
J Antimicrob Chemother, 47 (2001), pp. 811-818
[25.]
M.E. Klepser, E.J. Ernst, R. Petzold, P. Rhomberg, G.V. Doern.
Comparative bactericidal activities of ciprofloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Antimicrob Agents Chemother, 45 (2001), pp. 673-678
[26.]
C.E. Thorburn, D.I. Edwards.
The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance.
J Antimicrob Chemother, 48 (2001), pp. 15-22
[27.]
K. Nagai, T.A. Davies, B.E. Dewasse, M.R. Jacobs, P.C. Appelbaum.
Single and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
J Antimicrob Chemother, 48 (2001), pp. 365-374
[28.]
M. Boss, S. Mayer, A. Fischer, K. Köhrer, S. Scheuring, P. Heisig, et al.
In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes and Staphylococcus aureus.
Antimicrob Agents Chemother, 45 (2001), pp. 938-942
[29.]
S.F. Dowell, J.D. Heffelfinger.
Quinolones for community-acquired pneumonia.
Arch Intern Med, 161 (2001), pp. 1681-1682
[30.]
J. Hutchinson.
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
N Engl J Med, 347 (2002), pp. 65-67
[31.]
R.P. Wenzel, M.B. Edmond.
Managing antibiotic resistance.
N Engl J Med, 343 (2000), pp. 1961-1963
[32.]
Sociedad Española de Quimioterapia. Evaluación del consumo de antibióticos en atención primaria de salud (1999). Disponible en:http://www.seq.es/revista/0101/short/short1.html
[33.]
O. Cars, S. Mölstad, A. Melander.
Variation in antibiotic use in the European Union.
Lancet, 357 (2001), pp. 1851-1853
[34.]
C. García Rey, L. Aguilar, F. Baquero, Pathogens on behalf of the Spanish Surveillance Group for Respiratory.
Influence of different factors on the ciprofloxacin resistance prevalence of Streptococcus pneumoniae in Spain. Results of one-year (1996-97) multicenter surveillance study.
Antimicrob Agents Chemother, 44 (2000), pp. 3481-3482
[35.]
J.H. Williams.
Fluoroquinolones for respiratory infections. Too valuable to overuse.
Chest, 120 (2001), pp. 1771-1775
[36.]
M.T. Camacho, D. Vicioso, S. Berrón, I. Jado, J. Casal, A. Fenoll.
Serotipos y resistencia a antibióticos de Streptococcus pneumoniae (enero 1997-2001).
Enferm Infecc Microbiol Clin, 20 (2002), pp. 101
Copyright © 2003. Sociedad Española de Neumología y Cirugía Torácica
